IP Library › Patent Application 18236345

Patent Application

App. No. 18/236,345

Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 18/236,345

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention provides a composition comprising an antiviral agent and a C—X—C chemokine receptor type 4 (CXCR4) antagonist, and methods for using the same. Compositions and methods of the invention can be used to treat viral infection, immune disorders (e.g., rheumatoid arthritis), pulmonary fibrosis, or any other clinical condition associated with abnormal expression (e.g., overexpression and/or upregulation) of CXCR4. Compounds of the invention can also be used in stem cell therapeutics.

Claims (69)

1 . A composition comprising (i) an antiviral agent, and (ii) a CXCR4 antagonist of the formula:

or a pharmaceutically acceptable salt thereof, wherein

a is 0 or 1;

AA 1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine;

AA 2 along with the sulfur atom that is attached thereto is cysteine or homocysteine;

Ar 1 is an optionally substituted aryl;

X 1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Om(iPr), or Lys(iPr);

X 2 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Om(iPr), Lys(iPr), D-Arg, D-Dap, D-Dab, D-Orn, D-Lys, D-Dap(iPr), D-Dab(iPr), D-Om(iPr), D-Lys(iPr), or absent;

X 3 is Gly or absent;

X 4 is Phe, 2Nal, 1Nal, the D-isomer thereof, or absent; X 5 is Gly or absent;

R 2 is —OR 4 or —NHR 5 ;

R 4 is H or alkyl; and

R 5 is H, alkyl, optionally substituted aryl, optionally substituted aralkyl.

2 . The composition according to claim 1 , wherein said antiviral agent comprises abacavir, atazanavir, cobicistat, darunavir, didanosine, dolutegravir, efavirenz, elvitegravir, emtricitabine, enfuvirtide, fosamprenavir, hydroxychloroquine sulfate, indinavir, lamivudine, lopinavir, maraviroc, nelfinavir, raltegravir, ritonavir, saquinavir, stavudine, tenofovir disoproxil fumarate, tipranavir, zidovudine, or a combination thereof.

3 . The composition according to claim 1 , wherein the CXCR4 antagonist is of the formula:

or a pharmaceutically acceptable salt thereof, wherein:

a is an integer 0 or 1;

m and n are independently 1 or 2;

R 1 is H or NHR 3 , wherein R 3 is H, alkyl, acyl, optionally substituted aryl, optionally substituted aralkyl, —C(═O)—Ar a , wherein Ar a is optionally substituted aryl; and

Ar 1 , X 1 , X 2 , X 3 , X 4 , X 5 and R 2 are those defined in claim 1 .

4 . The composition according to claim 3 , wherein a=1 and Ar 1 is an optionally substituted phenyl.

5 . The composition according to claim 3 , wherein m=1 and n=1.

6 . The composition according to claim 3 , wherein m=1 and n=2.

7 . The composition according to claim 3 , wherein m=2 and n=1.

8 . The composition according to claim 1 , wherein X 2 is a (D)-isomer or absent.

9 . The composition according to claim 1 , wherein X 4 is a (D)-isomer or absent.

10 . The composition according to claim 3 , wherein R 1 is H and m=1.

11 . The composition according to claim 3 , wherein R 1 is Ac—NH and m=2.

12 . The composition according to claim 3 , wherein R 2 is —NH(Et), and X 4 and X 5 are absent.

13 . The composition according to claim 1 wherein the CXCR4 antagonist is selected from the group consisting of:

cyclo[Mpa-Tyr-Arg-(D-Arg)-2Nal-Gly-Cys]-Arg-Gly-(D-Phe)-Gly-NH 2 ;

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Arg-Gly-(D-Phe)-Gly-NH 2 ;

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-(D-Phe)-Gly-NH 2 ;

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-(D-Arg)-Gly-(D-Phe)-Gly-NH 2 ;

cyclo[Mpa-Arg-Tyr-Arg-2Nal-Gly-Cys]-Arg-Gly-(D-Phe)-Gly-NH 2 ;

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-(D-Phe)-Gly-NH(Et);

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-NH(Et);

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-2Nal-Gly-NH 2 ;

Ac-cyclo[hCys-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-(D-Phe)-Gly-NH 2 ;

Ac-cyclo[hCys-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-NH 2 ;

Benzoylcyclo[hCys-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-NH 2 ;

Benzoyl-cyclo[Cys-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-hCys]-Lys(iPr)-Gly-NH 2 ;

Benzoyl-cyclo[hCys-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-NH(Et);

Phenylacetyl-cyclo[hCys-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-NH 2 ;

Ac-cyclo[hCys-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Gly-NH(Et);

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Lys(Ac)—NH(Et);

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Lys(lauroyl)-NH(Et);

cyclo[Mpa-Tyr-Lys(iPr)-(D-Arg)-2Nal-Gly-Cys]-Lys(iPr)-Lys(palmitoyl)-NH(Et);

wherein each of m and n is independently 1 or 2; and

wherein R 3 is an alkyl or an acyl.

14 . The composition according to claim 3 , wherein m=1, n=1 and R 1 is NHR 3 , wherein R 3 is as defined in claim 1 .

15 . The composition according to claim 3 , wherein m=1, n=2, and R 1 is NHR 3 , wherein R 3 is as defined in claim 1 .

16 . The composition according to claim 3 , wherein m=2, n=1, and R 1 is NHR 3 , wherein R 3 is as defined in claim 1 .

17 . The composition according to claim 1 further comprising one or more pharmaceutically acceptable excipients.

18 . A method treating a subject suffering from a viral infection, said method comprising administering to a subject in need of such a treatment a therapeutically effective amount of a composition comprising (i) an antiviral agent, and (ii) a CXCR4 antagonist of the formula: